SCHEMBL4564104

SCHEMBL4564104

CC(C)(C)OC(=O)NN(C(=O)OC(C)(C)C)c1ccc(C=O)s1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 3/20 0.38
MAPT P10636 4/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 2/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.33
MIF P14174 1/20 0.33
CTSL P07711 2/20 0.32
CTSB P07858 2/20 0.32
CTSS P25774 2/20 0.32
RAB9A P51151 3/20 0.32
NPC1 O15118 2/20 0.32
ATR Q13535 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24716783 0.78 HPGD (0.43) AKT1MAPTMEN1KMT2AALDH1A1
SCHEMBL4564052 0.78 CTSS (0.41) AKT1LMNAPOLBMIFCTSL
SCHEMBL5069652 0.76 AKT1 (0.32) AKT1MAPTKDM4ERAB9ANPC1
SCHEMBL1781292 0.75 NPC1 (0.46) AKT1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL25541945 0.71 RAB9A (0.38) AKT1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL10565579 0.71 AKT1 (0.49) AKT1MAPTMEN1KMT2AALDH1A1
SCHEMBL24716815 0.70 TGM2 (0.45) POLB
SCHEMBL4550843 0.70 AKT1 (0.33) AKT1MAPTSMN1; SMN2LMNAKDM4E
SCHEMBL28420950 0.70 MIF (0.46) AKT1MAPTALDH1A1LMNAKDM4E
SCHEMBL369629 0.69 CTSS (0.38) AKT1MAPTALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
EP-2137158-A1 SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) MethylGene Inc. (CA) 2009-12-30 EP disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed
WO-2008104077-A1 SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) METHYLGENE INC. (CA) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280925-A1 Amines as Small Molecule Inhibitors CARM1, PRMT1, PRMT3 AKT1 95/4885MAPT 71/4885MEN1 2026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.